Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

[1]  Richard A. White,et al.  Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030 , 2017, BMC Infectious Diseases.

[2]  J. Mar,et al.  Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients , 2017, Expert review of gastroenterology & hepatology.

[3]  Karl Claxton,et al.  Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  Y. Yazdanpanah,et al.  Cost‐effectiveness and budget impact of interferon‐free direct‐acting antiviral‐based regimens for hepatitis C treatment: the French case , 2016, Journal of viral hepatitis.

[5]  J. Cairns,et al.  Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation , 2016, Journal of hepatology.

[6]  H. Parise,et al.  Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States , 2016, Advances in Therapy.

[7]  R. Faria,et al.  Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right? , 2016, PharmacoEconomics.

[8]  J. Chhatwal,et al.  Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals , 2016, PharmacoEconomics.

[9]  T. Brennan,et al.  Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus , 2015, Annals of Internal Medicine.

[10]  J. Ward,et al.  The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Mauss,et al.  No strategy to meet the HCV epidemic , 2014, BMC Infectious Diseases.

[12]  R. Marinho,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[13]  A. Bretteville-Jensen,et al.  Gender differences in mortality and risk factors in a 13-year cohort study of street-recruited injecting drug users , 2014, BMC Public Health.

[14]  J. Olsen,et al.  Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010 , 2014, PharmacoEconomics (Auckland).

[15]  S. Hutchinson,et al.  Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. , 2013, Journal of hepatology.

[16]  P. Vickerman,et al.  Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.

[17]  R. Kim,et al.  Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  L. Seeff.  The history of the “natural history” of hepatitis C (1968–2009) , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[19]  M. Aalabaf-Sabaghi.  Decision modelling for health economic evaluation , 2007, Journal of Epidemiology and Community Health.

[20]  Ron Goeree,et al.  Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another , 2007, Current medical research and opinion.

[21]  M. Colombo,et al.  The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients , 2006, Hepatology.

[22]  S. Bird,et al.  Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland , 2005, Hepatology.

[23]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[24]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[25]  G. Wells,et al.  Drugs for Chronic Hepatitis C Infection: Clinical Review , 2016 .

[26]  M. Krahn,et al.  Drugs for Chronic Hepatitis C Infection: Cost-Effectiveness Analysis , 2016 .

[27]  S. Jeansson,et al.  Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. , 2003, Scandinavian journal of gastroenterology.